Microbial Fermentation Technology Market Size, Share & Trends Analysis Report By Application (Antibiotics, Vaccines), By End-user (Biopharmaceutical Companies), By Region, And Segment- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2023-2032

The global microbial fermentation technology market size was exhibited at USD 31.98 billion in 2022 and is projected to hit around USD 56.73 billion by 2032, growing at a CAGR of 5.9% during the forecast period 2023 to 2032.

Microbial Fermentation Technology Market

Key Pointers:

  • The antibiotics segment captured the largest market share of 32.19% in 2022
  • The CMOs and CDMOs segment dominated the market and accounted for the highest share of 42.18% in 2022.
  • Owing to the faster and more stable growth pattern of microorganisms, the use of fermentation in small molecule synthesis is expected to witness lucrative growth throughout the forecast period
  • Furthermore, the demand for biologics and biopharmaceuticals is increasing in Japan. As a result, Japanese firms are undertaking various strategic initiatives to enhance their domestic biomanufacturing operations
  • North America is anticipated to witness the fastest growth throughout the forecast period owing to the presence of a well-established biopharmaceutical industry coupled with a high number of fermentation solution providers
  • Continuous efforts by key players to improve their product offerings are also contributing to North America’s regional market growth
  • Asia Pacific dominated the market and accounted for the highest revenue share of 45.11% in 2022. 

Microbial Fermentation Technology Market Report Scope

Report Coverage Details
Market Size in 2023 USD 3.87 Billion
Market Size by 2032 USD 56.73 Billion
Growth Rate From 2023 to 2032 CAGR of 5.9%
Base Year 2022
Forecast Period 2023 to 2032
Segments Covered Application, End-user,
Market Analysis (Terms Used) Value (US$ Million/Billion) or (Volume/Units)
Regional Scope North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa
Key Companies Profiled Biocon Ltd.; BioVectra Inc.; Danone UK; F. Hoffmann-La Roche Ltd.; Koninklijke DSM NV; Lonza; Novozymes A/S; TerraVia Holdings, Inc.;BIOZEEN

 

The factors such as increasing demand for biologics, development of innovative therapies based on smaller biologic drug substances, and advancements in microbial fermentation platforms/ technologies have driven the growth of the industry in recent years. In the past few years, the microbial fermentation space is witnessing an upsurge in demand owing to the exponential growth in the microbial biopharmaceutical industry. The advantages offered by microbial expression systems such as short-development timelines, higher expression levels, and less media cost as compared to mammalian cell culture have majorly contributed to the resurgence in interest in using microbial organisms in manufacturing processes. Overall, microbial fermentation technology offers higher yields, faster development, better scalability, reduced variation between batches along with lower production costs.

Amidst the COVID-19 pandemic, the microbial fermentation technology market was relatively less impacted. The surge in demand for various biologics resulted in growing attention toward microbial biotechnology. Market players involved in COVID-19 vaccine development and manufacturing have also relied on microbial expression systems for vaccine development. For instance, the Pfizer-BioNTech vaccine is based on bacterial fermentation for the production of DNA plasmids required for vaccine manufacturing.

Furthermore, increasing demand for microbial contract manufacturing services is anticipated to supplement the market growth. Currently, more than 115 industry participants are actively engaged in offering microbial fermentation services. Thus, the market is highly fragmented with the presence of well-established players such as AbbVie Contract Manufacturing, Lonza, and others. Such a high number of service providers in this market space are likely to spur market growth in the coming years.

Furthermore, yeasts are a commonly used eukaryotic host for the production of heterologous proteins and provide several advantages in the manufacturing of therapeutic recombinants. The use of yeast as a cell factory has various advantages, including simplicity of genetic manipulation, high cell density development, and post-translational modification possibilities. Thus, the rising focus of various research institutes and scientists on exploring the potential of yeast cells in therapeutic or clinical applications will expedite market growth in the near future.

Microbial Fermentation Technology Market Segmentation

By Application By End-user
  • Antibiotics
  • Probiotics Supplements
  • Monoclonal Antibodies
  • Recombinant Proteins
  • Biosimilars
  • Vaccines
  • Enzymes
  • Small Molecules
  • Others
  • Bio-Pharmaceutical Companies
  • Contract Research Organizations (CROs)
  • CMOs & CDMOs
  • Academic & Research Institutes

 

 

Frequently Asked Questions

The global microbial fermentation technology market size was exhibited at USD 31.98 billion in 2022 and is projected to hit around USD 56.73 billion by 2032

The global microbial fermentation technology market is expected to grow at a compound annual growth rate of 5.9% from 2023 to 2032

Key factors that are driving the market growth include growing demand for microbial contract manufacturing services, short-development time, higher expression levels, and high demand for antibiotics across the globe.

Some key players operating in the microbial fermentation technology market include Biocon Ltd., BioVectra Inc., Danone UK, F. Hoffmann-La Roche Ltd, Lonza, Novozymes A/S, BIOZEEN, and TerraVia Holdings, Inc.

Chapter 1. Methodology and Scope
                   1.1. Information Procurement
                   1.2. Information or Data Analysis
                   1.3. Market Scope & Segment Definition
                   1.4. Market Model
                       1.4.1. Market Study, By Company Market Share
                       1.4.2. Regional Analysis
Chapter 2. Executive Summary
                   2.1. Market Snapshot
                   2.2. Segment Snapshot
                   2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
                   3.1. Market Segmentation and Scope
                   3.2. Market Lineage Outlook
                       3.2.1. Parent Market Outlook
                       3.2.2. Related/Ancillary Market Outlook
                   3.3. Market Trends and Outlook
                   3.4. Market Dynamics
                       3.4.1. Increasing usage of fermentation technology-derived products among various industries
                       3.4.2. Rising research and development activities in different fields of fermentation technology
                       3.4.3. Exhausting fossil fuel reserves and rising gasoline prices
                   3.5. Market Restraint Analysis
                       3.5.1. Technological challenges associated with microbial fermentation
                   3.6. Penetration and Growth Prospect Mapping 2023
                   3.7. Business Environment Analysis
                       3.7.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
                       3.7.2. Porter’s Five Forces Analysis
                   3.8. COVID-19 Impact Analysis
Chapter 4. Application Business Analysis
                   4.1. Microbial Fermentation Technology Market: Product Movement Analysis
                   4.2. Antibiotics
                       4.2.1. Antibiotics Market, 2020 - 2032
                   4.3. Probiotics Supplements
                       4.3.1. Probiotics Supplements Market, 2020 - 2032
                   4.4. Monoclonal Antibodies
                       4.4.1. Monoclonal Antibodies Market, 2020 - 2032
                   4.5. Recombinant Proteins
                       4.5.1. Recombinant Proteins Market, 2020 - 2032
                   4.6. Biosimilars
                       4.6.1. Biosimilars Market, 2020 - 2032
                   4.7. Vaccines
                       4.7.1. Vaccines Market, 2020 - 2032
                   4.8. Enzymes
                       4.8.1. Enzymes Market, 2020 - 2032
                   4.9. Small Molecules
                       4.9.1. Small Molecules Market, 2020 - 2032
                   4.10. Others
                       4.10.1. Others Market, 2020 - 2032
Chapter 5. End-User Business Analysis
                   5.1. Microbial Fermentation Technology Market: End-User Movement Analysis
                   5.2. Biopharmaceutical Companies
                       5.2.1. Biopharmaceutical Companies Market, 2020 - 2032
                   5.3. Contract Research Organizations (CROs)
                       5.3.1. Contract Research Organizations (CROs) Market, 2020 - 2032
                   5.4. CMOs & CDMOs
                       5.4.1. CMOs & CDMOs Market, 2020 - 2032
                   5.5. Academic & Research Institutes
                       5.5.1. Academic & Research Institutes Market, 2020 - 2032
Chapter 6. Regional Business Analysis
                   6.1. Microbial Fermentation Technology Market Share By Region, 2023 & 2032
                   6.2. North America
                       6.2.1. SWOT Analysis
                       6.2.2. North America Microbial Fermentation Technology Market, 2020 - 2032
                       6.2.3. U.S.
                           6.2.3.1. Key Country Dynamics
                           6.2.3.2. Target Disease Prevalence
                           6.2.3.3. Competitive Scenario
                           6.2.3.4. Regulatory Framework
                           6.2.3.5. U.S. Microbial Fermentation Technology Market, 2020 - 2032
                       6.2.4. Canada
                           6.2.4.1. Key Country Dynamics
                           6.2.4.2. Target Disease Prevalence
                           6.2.4.3. Competitive Scenario
                           6.2.4.4. Regulatory Framework
                           6.2.4.5. Canada Microbial Fermentation Technology Market, 2020 - 2032
                   6.3. Europe
                       6.3.1. SWOT Analysis
                       6.3.2. Europe Microbial Fermentation Technology Market, 2020 - 2032
                       6.3.3. Germany
                           6.3.3.1. Key Country Dynamics
                           6.3.3.2. Target Disease Prevalence
                           6.3.3.3. Competitive Scenario
                           6.3.3.4. Regulatory Framework
                           6.3.3.5. Germany Microbial Fermentation Technology Market, 2020 - 2032
                       6.3.4. UK
                           6.3.4.1. Key Country Dynamics
                           6.3.4.2. Target Disease Prevalence
                           6.3.4.3. Competitive Scenario
                           6.3.4.4. Regulatory Framework
                           6.3.4.5. UK Microbial Fermentation Technology Market, 2020 - 2032
                       6.3.5. France
                           6.3.5.1. Key Country Dynamics
                           6.3.5.2. Target Disease Prevalence
                           6.3.5.3. Competitive Scenario
                           6.3.5.4. Regulatory Framework
                           6.3.5.5. France Microbial Fermentation Technology Market, 2020 - 2032
                       6.3.6. Italy
                           6.3.6.1. Key Country Dynamics
                           6.3.6.2. Target Disease Prevalence
                           6.3.6.3. Competitive Scenario
                           6.3.6.4. Regulatory Framework
                           6.3.6.5. Italy Microbial Fermentation Technology Market, 2020 - 2032
                       6.3.7. Spain
                           6.3.7.1. Key Country Dynamics
                           6.3.7.2. Target Disease Prevalence
                           6.3.7.3. Competitive Scenario
                           6.3.7.4. Regulatory Framework
                           6.3.7.5. Spain Microbial Fermentation Technology Market, 2020 - 2032
                       6.3.8. Denmark
                           6.3.8.1. Key Country Dynamics
                           6.3.8.2. Target Disease Prevalence
                           6.3.8.3. Competitive Scenario
                           6.3.8.4. Regulatory Framework
                           6.3.8.5. Denmark Microbial Fermentation Technology Market, 2020 - 2032
                       6.3.9. Sweden
                           6.3.9.1. Key Country Dynamics
                           6.3.9.2. Target Disease Prevalence
                           6.3.9.3. Competitive Scenario
                           6.3.9.4. Regulatory Framework
                           6.3.9.5. Sweden Microbial Fermentation Technology Market, 2020 - 2032
                       6.3.10. Norway
                           6.3.10.1. Key Country Dynamics
                           6.3.10.2. Target Disease Prevalence
                           6.3.10.3. Competitive Scenario
                           6.3.10.4. Regulatory Framework
                           6.3.10.5. Norway Microbial Fermentation Technology Market, 2020 - 2032
                   6.4. Asia Pacific
                       6.4.1. SWOT Analysis
                       6.4.2. Asia Pacific Microbial Fermentation Technology Market, 2020 - 2032
                       6.4.3. Japan
                           6.4.3.1. Key Country Dynamics
                           6.4.3.2. Target Disease Prevalence
                           6.4.3.3. Competitive Scenario
                           6.4.3.4. Regulatory Framework
                           6.4.3.5. Japan Microbial Fermentation Technology Market, 2020 - 2032
                       6.4.4. China
                           6.4.4.1. Key Country Dynamics
                           6.4.4.2. Target Disease Prevalence
                           6.4.4.3. Competitive Scenario
                           6.4.4.4. Regulatory Framework
                           6.4.4.5. China Microbial Fermentation Technology Market, 2020 - 2032
                       6.4.5. India
                           6.4.5.1. Key Country Dynamics
                           6.4.5.2. Target Disease Prevalence
                           6.4.5.3. Competitive Scenario
                           6.4.5.4. Regulatory Framework
                           6.4.5.5. India Microbial Fermentation Technology Market, 2020 - 2032
                       6.4.6. South Korea
                           6.4.6.1. Key Country Dynamics
                           6.4.6.2. Target Disease Prevalence
                           6.4.6.3. Competitive Scenario
                           6.4.6.4. Regulatory Framework
                           6.4.6.5. South Korea Microbial Fermentation Technology Market, 2020 - 2032
                       6.4.7. Australia
                           6.4.7.1. Key Country Dynamics
                           6.4.7.2. Target Disease Prevalence
                           6.4.7.3. Competitive Scenario
                           6.4.7.4. Regulatory Framework
                           6.4.7.5. Australia Microbial Fermentation Technology Market, 2020 - 2032
                       6.4.8. Thailand
                           6.4.8.1. Key Country Dynamics
                           6.4.8.2. Target Disease Prevalence
                           6.4.8.3. Competitive Scenario
                           6.4.8.4. Regulatory Framework
                           6.4.8.5. Thailand Microbial Fermentation Technology Market, 2020 - 2032
                   6.5. Latin America
                       6.5.1. SWOT Analysis
                       6.5.2. Latin America Microbial Fermentation Technology Market, 2020 - 2032
                       6.5.3. Brazil
                           6.5.3.1. Key Country Dynamics
                           6.5.3.2. Target Disease Prevalence
                           6.5.3.3. Competitive Scenario
                           6.5.3.4. Regulatory Framework
                           6.5.3.5. Brazil Microbial Fermentation Technology Market, 2020 - 2032
                       6.5.4. Mexico
                           6.5.4.1. Key Country Dynamics
                           6.5.4.2. Target Disease Prevalence
                           6.5.4.3. Competitive Scenario
                           6.5.4.4. Regulatory Framework
                           6.5.4.5. Mexico Microbial Fermentation Technology Market, 2020 - 2032
                       6.5.5. Argentina
                           6.5.5.1. Key Country Dynamics
                           6.5.5.2. Target Disease Prevalence
                           6.5.5.3. Competitive Scenario
                           6.5.5.4. Regulatory Framework
                           6.5.5.5. Argentina Microbial Fermentation Technology Market, 2020 - 2032
                   6.6. MEA
                       6.6.1. SWOT Analysis
                       6.6.2. MEA Microbial Fermentation Technology Market, 2020 - 2032
                       6.6.3. South Africa
                           6.6.3.1. Key Country Dynamics
                           6.6.3.2. Target Disease Prevalence
                           6.6.3.3. Competitive Scenario
                           6.6.3.4. Regulatory Framework
                           6.6.3.5. South Africa Microbial Fermentation Technology Market, 2020 - 2032
                       6.6.4. Saudi Arabia
                           6.6.4.1. Key Country Dynamics
                           6.6.4.2. Target Disease Prevalence
                           6.6.4.3. Competitive Scenario
                           6.6.4.4. Regulatory Framework
                           6.6.4.5. Saudi Arabia Microbial Fermentation Technology Market, 2020 - 2032
                       6.6.5. UAE
                           6.6.5.1. Key Country Dynamics
                           6.6.5.2. Target Disease Prevalence
                           6.6.5.3. Competitive Scenario
                           6.6.5.4. Regulatory Framework
                           6.6.5.5. UAE Microbial Fermentation Technology Market, 2020 - 2032
                       6.6.6. Kuwait
                           6.6.6.1. Key Country Dynamics
                           6.6.6.2. Target Disease Prevalence
                           6.6.6.3. Competitive Scenario
                           6.6.6.4. Regulatory Framework
                           6.6.6.5. Kuwait Microbial Fermentation Technology Market, 2020 - 2032
Chapter 7. Competitive Landscape
                   7.1. Company Categorization
                   7.2. Company Market Share Analysis, 2023
                   7.3. Strategy Mapping
                       7.3.1. Expansion
                       7.3.2. Acquisition
                       7.3.3. Collaborations
                       7.3.4. Product/Therapeutic Area Launch
                       7.3.5. Partnerships
                       7.3.6. Others
                   7.4. Participant’s overview
                       7.4.1. Biocon Ltd.
                           7.4.1.1. Overview
                           7.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           7.4.1.3. Product Benchmarking
                           7.4.1.4. Strategic Initiatives
                       7.4.2. BioVectra Inc.
                           7.4.2.1. Overview
                           7.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           7.4.2.3. Product Benchmarking
                           7.4.2.4. Strategic Initiatives
                       7.4.3. Danone UK
                           7.4.3.1. Overview
                           7.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           7.4.3.3. Product Benchmarking
                           7.4.3.4. Strategic Initiatives
                       7.4.4. F. Hoffmann-La Roche AG
                           7.4.4.1. Overview
                           7.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           7.4.4.3. Product Benchmarking
                           7.4.4.4. Strategic Initiatives
                       7.4.5. Koninklijke DSM NV
                           7.4.5.1. Overview
                           7.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           7.4.5.3. Product Benchmarking
                           7.4.5.4. Strategic Initiatives
                       7.4.6. Lonza
                           7.4.6.1. Overview
                           7.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           7.4.6.3. Product Benchmarking
                           7.4.6.4. Strategic Initiatives
                       7.4.7. Novozymes A/S
                           7.4.7.1. Overview
                           7.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           7.4.7.3. Product Benchmarking
                           7.4.7.4. Strategic Initiatives
                       7.4.8. TerraVia Holdings, Inc.
                           7.4.8.1. Overview
                           7.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           7.4.8.3. Product Benchmarking
                           7.4.8.4. Strategic Initiatives
                       7.4.9. BIOZEEN
                           7.4.9.1. Overview
                           7.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           7.4.9.3. Product Benchmarking
                           7.4.9.4. Strategic Initiatives

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers
Ask To Expert